Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
based on MRD clearance in 24 patients , with a prespecified bar of an absolute 25–30% MRD clearance improvement for cema-cel versus observation; the randomized ~220-patient study uses event-free survival as the primary endpoint. Management says its "Allogene XL" allogeneic CAR-T can be manufactured at “biologic-like” scale (~ 20,000–60,000 doses/year ) with estimated cost of goods of $10,000–$20,000 per dose, and frames a commercial opportunity of ~ MRD-positive/insufficiently treated patients in the U.S. and Europe (~ $5 billion TAM) with potential peak sales well over $2 billion The autoimmune program ALLO-329 is a dual CD19/CD70 "Dagger" allogeneic CAR-T designed to enable lighter or no lymphodepletion (starting at 20M cells with Cy-only and no-LD cohorts), with initial proof-of-concept and biomarker readouts expected in June 2026 Interested in Allogene Therapeutics, Inc.? Here are five stocks we like better. 3 Stocks With Sky-High Short Interest Levels Allogene Therapeut
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business UpdateGlobeNewswire
- Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALLO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- ??·?????????????????2035????1,831????????????????? [CNET News]CNET News
ALLO
Earnings
- 11/6/25 - Beat
ALLO
Sec Filings
- 3/4/26 - Form 4
- 3/2/26 - Form 144
- 2/17/26 - Form SCHEDULE
- ALLO's page on the SEC website